Alarelin Acetate|CAS 79561-22-1|DC Chemicals

Cas No.:	79561-22-1
Chemical Name:	Alarelin acetate
Synonyms:	des-gly10(D-ala6) luteinizing hormone*releasing H;DES-GLY10,[D-ALA6]-LH-RH ETHYLAMIDE ACETATE SALT;(DES-GLY10,D-ALA6,PRO-NHET9)-LHRH;(DES-GLY10,D-ALA6,PRO-NHET9)-GONADOTROPIN-RELEASING HORMONE (SEA BREAM);(DES-GLY10,D-ALA6,PRO-NHET9)-GONADOTROPIN-RELEASING HORMONE;(DES-GLY10,D-ALA6,PRO-NHET9)-LUTEINIZING HORMONE-RELEASING FACTOR (SEA BREAM);(DES-GLY10,D-ALA6,PRO-NHET9)-LUTEINIZING HORMONE-RELEASING FACTOR;(DES-GLY10,D-ALA6,PRO-NHET9)-LHRH (SEA BREAM);[DES-GLY10, D-ALA6, PRO-NHET9]-LH-RH (HUMAN);Alarelin Acetate;[D- ALA6 ,DES-GLY10 ]-LH-RH ETHYLAMIDE;Alarelin;(DES-GLY10 D-ALA6)-LH-RH ETHYLAMIDE ACE;Alareline Acetate;Amp:Adenosine-5-MonophosphateFreeAcid;GLP-HIS-TRP-SER-TYR-D-ALA-LEU-ARG-PRO-NHET;LHRH,Ala(6)-Gly(10)-ethylamide;SURFAGON;10-Des-gly,6-(D-ala)-LHRH ethylamide, acetate salt;6-D-Ala-10-D-gly-LHRH-ethylamide;Ala(6)-gly(10)-gnrh;LHRH, alanine(6)-glycine(10)-ethylamide-;LHRH-A;des-Gly(sup 10),(D-Ala(sup 6))-LHRH-ethylamide;Luteinizing hormone-releasing factor(pig), 6-D-alanine-9-(N-ethyl-L-prolinamide)-10-deglycinamide-, diacetate (salt);Alarelin (Acetate);Dalareline;Alarelin Acetate/;C56H78N16O12;LH-RHa;GTPL9342;ABP000561;K410
SMILES:	O=C([C@]([H])(C([H])([H])C([H])([H])C([H])([H])/N=C(\N([H])[H])/N([H])[H])N([H])C([C@]([H])(C([H])([H])C([H])(C([H])([H])[H])C([H])([H])[H])N([H])C([C@@]([H])(C([H])([H])[H])N([H])C([C@]([H])(C([H])([H])C1C([H])=C([H])C(=C([H])C=1[H])O[H])N([H])C([C@]([H])(C([H])([H])O[H])N([H])C([C@]([H])(C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12)N([H])C([C@]([H])(C([H])([H])C1=C([H])N=C([H])N1[H])N([H])C([C@]1([H])C([H])([H])C([H])([H])C(N1[H])=O)=O)=O)=O)=O)=O)=O)=O)N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(N([H])C([H])([H])C([H])([H])[H])=O
Formula:	C₅₆H₇₈N₁₆O₁₂
M.Wt:	1167.3185
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Cat. No.	Product name	Field of application
DC31074	Isopropyl myristate	Isopropyl myristate is the ester of isopropyl alcohol and myristic acid.
DC75868	AZ14133346	AZ14133346 (compound 36) is a potent and selective inhibitor of EGFR Exon20 insertions, with the IC50 of 85 nM. AZ14133346 plays an important role in cancer research.
DC75865	TI17	TI17 represents a novel class of targeted anticancer agents that specifically disrupt DNA damage repair mechanisms in malignant cells.
DC75816	Nisoxetine	Nisoxetine acts as a highly selective and potent noradrenaline transporter (NET) antagonist, exhibiting a binding affinity (Kd) of 0.76 nM. In addition to its antidepressant properties, nisoxetine functions as a local anesthetic by inhibiting voltage-gated sodium channels. This dual pharmacological activity makes it a compound of interest for both neurological and pain management research.
DC75641	GENZ-644282 TFA salt	Genz-644282, also known as SAR402674, is a non-camptothecin inhibitor of topoisomerase I with potential antineoplastic activity. Topoisomerase I inhibitor Genz-644282 binds to and inhibits the enzyme topoisomerase I, which may result in the inhibition of repair of single-strand DNA breaks, DNA replication, and tumor cell growth in susceptible tumor cell populations.
DC75325	PSMA-617 TFA	PSMA-617, also know as vipivotide tetraxetan, is a ligand used to make 177Lu-PSMA-617, which is a radioactive molecule to fight cancer. PSMA617 possesses a small peptide, which was designed to target prostate-specific membrane antigen (PSMA). PSMA617 demonstrates high radiolytic stability for at least 72 h. PSMA617 has high inhibition potency (equilibrium dissociation constant Ki=2.34±2.94 nM on LNCaP; Ki=0.37±0.21 nM enzymatically determined). 177 Lu-PSMA-617 offers a potential additional life-prolonging treatment option for men with mCRPC.
DC75202	Fosaprepitant free acid	Fosaprepitant, also known as MK0517, is an antiemetic drug, administered intravenously. It is a prodrug of aprepitant. Fosaprepitant was developed by Merck & Co. and was approved. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. Fosaprepitant is a weak inhibitor of CYP3A4, and aprepitant, the active moiety, is a substrate, inhibitor, and inducer of CYP3A4
DC74748	O4I4	O4I4 (compound 23) is a OCT4-inducing compound with metabolical stability.
DC74684	ZH8667	ZH8667 is a trace amine-associated receptor 1 (TAAR1)–Gs agonist.
DC74646	EB-PSMA-617	EB-PSMA-617 is an Evans blue-modified prostate-specific membrane antigen (PSMA) 617 ligand for making 177Lu-EB-PSMA, which is potential useful for Metastatic Castration-Resistant Prostate Cancer.